A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder
Latest Information Update: 01 Nov 2025
At a glance
- Drugs VQW 765 (Primary)
- Indications Social phobia
- Focus Registrational; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
Most Recent Events
- 01 Nov 2025 New trial record